Verastem, Inc. Form 10-K Summary
Business context and reporting period
Verastem is a clinical-stage biopharmaceutical company developing small-molecule oncology therapies intended to target cancer stem cells. Its principal programs were the FAK inhibitors VS-6063 (defactinib) and VS-4718, and the dual PI3K/mTOR inhibitor VS-5584. The filing covers the fiscal year ended December 31, 2014, with comparative results for 2012 and 2013.
The company had no approved products and had generated no revenue. VS-6063 was the lead program, including the registration-directed COMMAND trial in mesothelioma and additional studies in ovarian cancer, non-small cell lung cancer and mesothelioma. VS-4718 and VS-5584 were in Phase 1 trials.
Financial condition and key metrics
| Metric | 2014 | 2013 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No change |
| Research and development expense | $35.4 million | $25.9 million | Up $9.5 million |
| General and administrative expense | $18.2 million | $15.5 million | Up $2.7 million |
| Total operating expenses | $53.6 million | $41.4 million | Up $12.2 million |
| Net loss | $53.4 million | $41.2 million | Loss increased $12.2 million |
| Net loss per share | $2.07 | $1.82 | Loss per share increased |
| Cash used in operating activities | $36.9 million | $26.3 million | Use increased $10.6 million |
| Cash, cash equivalents and investments | $92.7 million | $123.7 million | Down $31.0 million |
| Working capital | $86.1 million | $94.2 million | Down $8.0 million |
| Accumulated deficit | $141.0 million | $87.7 million | Increased $53.4 million |
There was no material debt reported. Total liabilities were $9.9 million at December 31, 2014, including $9.2 million of current liabilities and $0.7 million of other liabilities. Stockholders’ equity was $88.8 million, compared with $117.4 million at year-end 2013.
Operating cash use increased primarily because of higher clinical development and research spending. Investing activities provided $43.1 million, mainly from net maturities of investments, while financing activities provided $8.8 million, primarily from the at-the-market equity offering program. The company reported no meaningful operating margin because it had no revenue and remained loss-making.
Material changes versus the prior comparable period
- Research and development expense increased 37% to $35.4 million, driven principally by a $7.6 million increase in contract research organization and outsourced clinical and development costs, higher personnel costs and increased occupancy expenses.
- General and administrative expense increased 17%, primarily because of higher stock-based compensation, consulting expenses related to potential commercialization, salaries and headcount.
- Stock-based compensation expense increased to approximately $12.1 million in 2014 from approximately $10.4 million in 2013.
- Cash, cash equivalents and investments declined to $92.7 million from $123.7 million despite $8.8 million of financing cash inflows.
- The company moved into a larger Needham, Massachusetts facility. Property and equipment increased to $2.8 million from $0.6 million, and total contractual operating lease obligations were $2.5 million.
- In February 2014, Verastem acquired intellectual property related to VS-4718 from Encarta for $25,000, 97,500 common shares and a warrant to purchase 142,857 shares at $17.16 per share. The transaction produced approximately $1.2 million of research and development expense.
Clinical outlook, risks and unusual items
- COMMAND had enrolled 180 patients as of January 8, 2015, was open in 13 countries and 55 centers, and was expected to enroll 350 to 400 patients by the end of 2015. An interim analysis was expected in the second quarter of 2015, with the primary efficacy readout anticipated in 2016.
- Management expected additional VS-6063 data in the second half of 2015, preliminary extended-treatment data from the mesothelioma surgery study in the first half of 2016, and Phase 1 results for VS-4718 and VS-5584 in the second half of 2015.
- Management expected existing cash, cash equivalents and investments, including approximately $55.5 million of net proceeds from January 2015 equity offerings, to fund the current operating plan into the first half of 2017. This estimate was dependent on clinical timing, enrollment, results and spending assumptions.
- In January 2015, the company raised approximately $50.9 million of net proceeds from a follow-on offering and approximately $2.5 million from additional at-the-market sales.
- The company expected continuing operating losses and stated that substantial additional funding would be required. It had no committed external source of funds and might need additional equity, debt, collaborations or licensing transactions.
- Key risks include failure or delay of clinical trials, inconclusive efficacy or safety results, slow patient enrollment, regulatory nonapproval, reliance on contract research organizations and third-party manufacturers, intellectual-property challenges, competition, reimbursement uncertainty and future dilution from equity financing.
- Clinical data cited for ovarian cancer, NSCLC and the mesothelioma window-of-opportunity study were preliminary or based on ongoing studies. The filing cautioned that early-stage or unaudited data may not predict later trial outcomes.
- The filing reported a fourth-quarter 2014 net loss of $13.9 million in the quarterly table, but the displayed amount lacks the expected negative sign; the filing text does not provide a fully clear quarterly presentation.
Most important facts to verify
- Confirm the final COMMAND enrollment, interim analysis, primary efficacy results and regulatory path for VS-6063.
- Reconcile the quarterly financial table’s fourth-quarter net-loss sign and verify the audited annual figures.
- Assess cash runway against actual quarterly operating cash burn, clinical enrollment and development costs.
- Review post-year-end equity issuance, dilution and the remaining availability under the at-the-market program.
- Evaluate potential milestone, royalty and license obligations, particularly those tied to Pfizer, Scripps, S*Bio and the Whitehead Institute.
- Monitor adverse events, clinical holds, regulatory requirements and the need for a companion diagnostic based on merlin expression.